A randomized open labelled comparative clinical study to evaluate the efficacy of Virechana with and without Snehapurva Rukshana in the management of Dyslipidemia
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Changes in Serum Lipid levels
研究概览
简要总结
Dyslipidemia is the most important atherosclerotic risk factor. Review of population based studies in India shows increasing mean total cholesterol levels. Recent studies reported that high cholesterol is present in 25-30% of urban and 15-20% of rural subjects. In modern science, Statins are the first choice in the treatment of Dyslipidemia, however the need for long term, lifelong therapy with statins is associated with several adverse effects like myopathy, increased risk of acute and chronic renal failure, hypothyroidism and memory loss. Thus, Considering the facts, A comparative clinical study is proposed to compare the efficacy of virechana with and without snehapurva rukshana in the management of dyslipidemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- Open Label
入排标准
- 年龄范围
- 21.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •subjects diagnosed with dyslipidemia with any of the serum lipid levels, S. Cholesterol.
- •200-500mg/dl S. Triglycerides.
- •150-400mg/dl HDL.
- •<40mg/dl LDL.
- •130-400mg/dl Subjects fit for Snehapana, Swedana, Udwartana and Virechana VLDL.
排除标准
- •Subjects unfit for snehapana, swedana, udwartana and virechana.
- •Subjects with type 1 diabetes, uncontrolled diabetes mellitus, uncontrolled hypertension, cardiovascular diseases Dyslipidemia due to endocrine or renal pathologies Dyslipidemia due to drugs e.g. glucocorticoids etc Pregnant and lactating women.
结局指标
主要结局
Changes in Serum Lipid levels
时间窗: Before treatment, | After treatment - next day of Virechana, | On follow up - after 15 days of Samsarjana krama
次要结局
未报告次要终点